These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
532 related articles for article (PubMed ID: 15853661)
41. Altered states: selectively drugging the Hsp90 cancer chaperone. Workman P Trends Mol Med; 2004 Feb; 10(2):47-51. PubMed ID: 15106614 [TBL] [Abstract][Full Text] [Related]
42. The Hsp90 chaperone complex as a novel target for cancer therapy. Goetz MP; Toft DO; Ames MM; Erlichman C Ann Oncol; 2003 Aug; 14(8):1169-76. PubMed ID: 12881371 [TBL] [Abstract][Full Text] [Related]
44. Engineered biosynthesis of geldanamycin analogs for Hsp90 inhibition. Patel K; Piagentini M; Rascher A; Tian ZQ; Buchanan GO; Regentin R; Hu Z; Hutchinson CR; McDaniel R Chem Biol; 2004 Dec; 11(12):1625-33. PubMed ID: 15610846 [TBL] [Abstract][Full Text] [Related]
45. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Maloney A; Workman P Expert Opin Biol Ther; 2002 Jan; 2(1):3-24. PubMed ID: 11772336 [TBL] [Abstract][Full Text] [Related]
46. Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art. Mellatyar H; Talaei S; Pilehvar-Soltanahmadi Y; Barzegar A; Akbarzadeh A; Shahabi A; Barekati-Mowahed M; Zarghami N Biomed Pharmacother; 2018 Jun; 102():608-617. PubMed ID: 29602128 [TBL] [Abstract][Full Text] [Related]
47. Cks1 proteasomal degradation is induced by inhibiting Hsp90-mediated chaperoning in cancer cells. Khattar V; Fried J; Xu B; Thottassery JV Cancer Chemother Pharmacol; 2015 Feb; 75(2):411-20. PubMed ID: 25544127 [TBL] [Abstract][Full Text] [Related]
48. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level. Yu W; Rao Q; Wang M; Tian Z; Lin D; Liu X; Wang J Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582 [TBL] [Abstract][Full Text] [Related]
49. Heat shock protein 90-dependent (geldanamycin-inhibited) movement of the glucocorticoid receptor through the cytoplasm to the nucleus requires intact cytoskeleton. Galigniana MD; Scruggs JL; Herrington J; Welsh MJ; Carter-Su C; Housley PR; Pratt WB Mol Endocrinol; 1998 Dec; 12(12):1903-13. PubMed ID: 9849964 [TBL] [Abstract][Full Text] [Related]
50. Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity. Zhang H; Yang YC; Zhang L; Fan J; Chung D; Choi D; Grecko R; Timony G; Karjian P; Boehm M; Burrows F Int J Cancer; 2007 Feb; 120(4):918-26. PubMed ID: 17131314 [TBL] [Abstract][Full Text] [Related]
51. Specific association of a set of molecular chaperones including HSP90 and Cdc37 with MOK, a member of the mitogen-activated protein kinase superfamily. Miyata Y; Ikawa Y; Shibuya M; Nishida E J Biol Chem; 2001 Jun; 276(24):21841-8. PubMed ID: 11278794 [TBL] [Abstract][Full Text] [Related]
52. Binding of immunophilins to the 90 kDa heat shock protein (hsp90) via a tetratricopeptide repeat domain is a conserved protein interaction in plants. Owens-Grillo JK; Stancato LF; Hoffmann K; Pratt WB; Krishna P Biochemistry; 1996 Dec; 35(48):15249-55. PubMed ID: 8952474 [TBL] [Abstract][Full Text] [Related]
53. Radester, a novel inhibitor of the Hsp90 protein folding machinery. Shen G; Blagg BS Org Lett; 2005 May; 7(11):2157-60. PubMed ID: 15901158 [TBL] [Abstract][Full Text] [Related]
54. Cdk2: a genuine protein kinase client of Hsp90 and Cdc37. Prince T; Sun L; Matts RL Biochemistry; 2005 Nov; 44(46):15287-95. PubMed ID: 16285732 [TBL] [Abstract][Full Text] [Related]
55. Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy. Franke J; Eichner S; Zeilinger C; Kirschning A Nat Prod Rep; 2013 Oct; 30(10):1299-323. PubMed ID: 23934201 [TBL] [Abstract][Full Text] [Related]
56. 17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types. Gossett DR; Bradley MS; Jin X; Lin J Gynecol Oncol; 2005 Feb; 96(2):381-8. PubMed ID: 15661225 [TBL] [Abstract][Full Text] [Related]
57. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition. Lin Z; Peng R; Li Z; Wang Y; Lu C; Shen Y; Wang J; Shi G Int J Mol Med; 2015 Aug; 36(2):424-32. PubMed ID: 26059743 [TBL] [Abstract][Full Text] [Related]
58. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy. Hwang M; Moretti L; Lu B Curr Med Chem; 2009; 16(24):3081-92. PubMed ID: 19689285 [TBL] [Abstract][Full Text] [Related]
59. Conformational significance of EH21A1-A4, phenolic derivatives of geldanamycin, for Hsp90 inhibitory activity. Onodera H; Kaneko M; Takahashi Y; Uochi Y; Funahashi J; Nakashima T; Soga S; Suzuki M; Ikeda S; Yamashita Y; Rahayu ES; Kanda Y; Ichimura M Bioorg Med Chem Lett; 2008 Mar; 18(5):1588-91. PubMed ID: 18243703 [TBL] [Abstract][Full Text] [Related]
60. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Tian ZQ; Liu Y; Zhang D; Wang Z; Dong SD; Carreras CW; Zhou Y; Rastelli G; Santi DV; Myles DC Bioorg Med Chem; 2004 Oct; 12(20):5317-29. PubMed ID: 15388159 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]